Effect of ke-298 on experimental arthritis in mice

Pharmacology

Volumn 53, Issue 3, 1996, Pages 190-196

  Nagai, Hiroichi ^a   Takaoka, Yuko ^a   Mori, Hiroshi ^a   Kawada, Kenji ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Collagen induced arthritis; Interleukin 1 beta; KE 298; Tumor necrosis factor alpha

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; COLLAGEN ANTIBODY; COLLAGEN TYPE 2; ESONARIMOD; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE INJURY; DELAYED HYPERSENSITIVITY; FEMALE; FOOT PAD; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029858027     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139430     Document Type: Article

References (29)

1. Kameo K, Ogawa K, Takcshita K, Nakaike Shiro, Tomiyama K, Sota K: Studies on anti-rheumatic agents: 3-Benzoylpropionic acid derivatives, Chem Pharm Bull 1988:36: 2050-2060.
2. Colier DSJ, Pain JA: Non-steroidal anti-inflammatory drugs and peptic ulcer perforation, Gut 1985:26:359-363.
3. Armstorong CP, Blower AL: Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration, Gut 1987;28: 527-532.
4. Skander MP, Ryan FP: Non-steroidal anti-inflammatory drugs and pain free peptic ulceration in the elderly, Br Med J 1988:297:833-834.
5. Scott DL, Symntons DPM, Coulton BL: Long term outcome of treating rheumatoid arthritis: Results after 20 years, Lancet 1987;Vol i: 1108-1111.
6. Takcshita K, Fukazawa I, Futaki N, Kameo K, Tomisawa K, Otomo S, Aihara H: Immunopharmacological studies of new 3-bcnzoyl-4-mercap-tobutvric acids, lmmunomodulating effects, Arzneimittcll'orschung 1988: 38:537-542.
7. Courtenay JS, Mosedale B: Immunization against heterologous type II collagen induces arthritis in mice, Nature 1980:283:666-668.
8. Trentham DE, Dyncsius-Trentham RA: Attenuation of an adjuvant arthritis by type II collagen, J Immunol 1983;130:2689-2692.
9. Trentham DE, Townes AS, Kang AH: Autoimmunity to type II collagen: An experimental model of arthritis, J Exp Med 1977:146:857-868.
10. Wooley PH, Luthra HS, Stuart JM, David CS: Type II collagen induced arthritis in mice, I, Major histocompatibility complex (I-region) linkage and antibody correlates, J Exp Med 1981:154:688-700.
11. Takcoka Y, Naiki M, Taguchi N, Intai H, Kurimato Y, Morita S, Sue-hiro S: 2-Buten-4-olide (2-B40) inhibits type II collagen-induced arthritis in Lewis rats, Int J Immuno-pharntacol 1993;15:803-810.
12. Fuchigami H, Nishimura T, Moto-naga A, Inouc Y, lnouc K, Suzuka H, Yoshifusa H, Kintura K, Mura-matu M: Effect of aclarit on type II collagen-induced arthritis in mice, Arzneimittclforschung 1994:44:64-68.
13. Griffiths RJ, Pcttipher ER, Kouch K, Farrell CA, Breslow R, Conklyn MJ, Smith MA, Hackman BC, Wimberly DJ, Milici AJ, Scampoli DN, Chcng JB, Pillar JS, Pazoles CJ, Doherty NA, Mclvink LS, Reiter LA, Biggars MS, Falkncr FC, Mitchell DY, Liston TE, Showed HJ: Leu-kotricne Bj plays a critical role in the progression of collagen-induced arthritis, Proc Natl Acad Sci USA 1995:92:517-521.
14. Eastgate JA: Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis, Lancet 1988;Vol ii:706-709.
15. Tctta C, Giovanni C, Vittorio M, Chiara DV, Corrado B: Tumor necrosis factor in scrum and synovial fluid of patients with active and severe rheumatoid arthritis, Ann Rheum Dis 1990:49:665-667.
16. Thorbecke GJ, Shall R, Leu CH, Kuruvilla AP, Hardison AM, Palla-dino MA: Involvement of endogenous tumor necrosis factor-a and transforming growth factor-p during induction of collagen type II arthritis in mice, Proc Natl Acad Sci USA 1992:89:7375-7379.
17. Chikanza IC, Kingsley G, Panayi GS: Peripheral blood and synovial fluid monocyte expression of interleukin la and Ip during active rheumatoid arthritis, J Rheumatol 1995; 22:600-606.
18. Chandrasekhar S, Harvey AK, Hru-bey PS, Bendelc KA: Arthritis induced by interleukin-1 is dependent on the site and frequency of intraar-ticular injection, Clin Immunol Im-munopathol 1990;55:382-400.
19. Staite ND, Richard KA, Aspar DG, Franz KA, Galinet LA, Dunn CJ: Induction of an acute erosive monoarticular arthritis in mice by inter-lcukin-1 and methylated bovine serum albumin, Arthritis Rheum 1990;33:253-260.
20. Loo AAJ, Arntz OJ, BergWB: Flare-up experimental arthritis in mice with murine recombinant IL-L Clin Exp Immunol 1992;87:196-202.
21. Brahn E, Peacock DJ, Banqucrigo ML, Liu DY: Effects of tumor necrosis factor alpha (TNFa) on collagen-induced arthritis, Lymphokine Cytokine Res 1992:11:253-256.
22. Cooper WO, Fava RA, Gates CA, Cremer MA, Townes AS: Acceleration of onset of collagen-induced arthritis by intraarticular injection of tumor necrosis factor or transforming growth factor-beta, Clin Exp Immunol 1992;898:244-250.
23. Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis, Proc Natl Acad Sci USA 1992;89:9784-9788.
24. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lcsslauer W: Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or recombinant soluble TNF receptor, Immunology 1992: 77:510-514.
25. Williams RO, Mason LJ, Feldmann M, Maini RN: Synergy between anti-CD-4 and tumor necrosis factor in the amelioration of established collagen-induced arthritis, Proc Natl Acad Sci USA 1994:91:2762-2766.
26. Williams RO, Ghrayeb J, Feldmann M, Maini RN: Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4, Immunology 1995;83:433-439.
27. Loo AA, Arntz OJ, Ottcmess IG, Berg WB: Protection against cartilage proteoglycan synthesis inhibition by anti-interleukin 1 antibodies in experimental arthritis, J Rheumatol 1992;19:328-356.
28. Joosten LAB, Helsen MMA, Loo FAJ, Berg WB: Amelioration of established collagen-induced arthritis (CIA) with anti-IL-1, Agents Actions 1994:41:074-076.
29. Labsack ME, Paul CC, Marlindalc JJ, Catalano MA: Subcutaneous IL-1 receptor antagonist patients with rheumatoid arthritis, Arthritis Rheum 1991:34: S45.